Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Synmosa BiopharmaROCO:4114 -3.87%84 PEG Ratio is 2.71 as of Jul. 20, 2026, which is 317% above its 10-year median of 0.65. GuruFocus rates ROCO:4114 with a GF Score™ of 84/100 and a GF Value™ of NT$33.93 (Modestly Undervalued). The stock has 1 warning sign investors should review. Among 350 Drug Manufacturers companies, Synmosa Biopharma ranks worse than 65.14% on this metric.
* The 5-Year EBITDA Growth Rate is the 5-year average EBITDA per share growth rate. While the denominator is a percentage, we use the whole number as opposed to the decimal form for the calculation. For example, 5% would be shown as 5 as opposed to 0.05. If it's smaller than or equal to 0, then the PEG Ratio is not calculated.
The historical rank and industry rank for Synmosa Biopharma's PEG Ratio or its related term are showing as below:
ROCO:4114'
s PEG Ratio Range Over the Past 10 Years
Min: 0.13 Med: 0.65 Max: 12.74
Current: 2.71
During the past 13 years, Synmosa Biopharma's highest PEG Ratio was 12.74. The lowest was 0.13. And the median was 0.65.
ROCO:4114's PEG Ratio is ranked worse than 65.14% of 350
companies
in the Drug Manufacturers industry
Industry Median: 1.825
vs ROCO:4114: 2.71
Peter Lynch thinks a company with a P/E ratio equal to its growth rate is fairly valued.
Synmosa Biopharma (ROCO:4114) PEG Ratio Explanation
To compare stocks with different growth rates, Peter Lynch invented a ratio called PEG Ratio. PEG Ratio is defined as the P/E ratio divided by the growth ratio. He thinks a company with a P/E ratio equal to its growth rate is fairly valued. Still he said he would rather buy a company growing 20% a year with a P/E of 20, instead of a company growing 10% a year with a P/E of 10.
Synmosa Biopharma PEG Ratio Related Terms
Synmosa Biopharma PEG Ratio Historical Data
* Premium members only.
The historical data trend for Synmosa Biopharma's PEG Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Synmosa Biopharma's PEG Ratio, along with its competitors' market caps and PEG Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Synmosa Biopharma PEG Ratio vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Synmosa Biopharma's PEG Ratio distribution charts can be found below:
* The bar in red indicates where Synmosa Biopharma's PEG Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* Note: The 5-Year EBITDA Growth Rate is the 5-year average EBITDA per share growth rate. While the denominator is a percentage, we use the whole number as opposed to the decimal form for the calculation. For example, 5% would be shown as 5 as opposed to 0.05. If it's smaller than or equal to 0, then the PEG Ratio is not calculated.
Synmosa Biopharma (ROCO:4114) has a PEG Ratio of 2.71 as of Jul. 20, 2026. Price-earnings to growth ratio is the ratio of price-earnings to a company's earnings growth rate. View historical data on Synmosa Biopharma and its competitors. This is 317% above median its historical median of 0.65. Over the past decade, Synmosa Biopharma's PEG Ratio has ranged from 0.13 to 12.74. According to the industry distribution chart, Synmosa Biopharma ranks #228 out of 350 companies in the Drug Manufacturers industry, placing it in the top 65.1%.
Is Synmosa Biopharma's PEG Ratio too high?
Synmosa Biopharma's current PEG Ratio of 2.71 is 317% above median its 10-year median of 0.65. Over the past 10 years, this metric has ranged from a low of 0.13 to a high of 12.74. The Drug Manufacturers industry median PEG Ratio is 1.83. Synmosa Biopharma's value of 2.71 is 48.5% above this industry median. Based on the distribution chart, Synmosa Biopharma ranks #228 out of 350 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Synmosa Biopharma has a GF Score™ of 84/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Synmosa Biopharma's PEG Ratio compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Synmosa Biopharma ranks #228 out of 350 companies for PEG Ratio. This places Synmosa Biopharma in the lower half of its industry. The industry median PEG Ratio is 1.83. Synmosa Biopharma's value of 2.71 is 48.5% above this benchmark. Historically, Synmosa Biopharma's own PEG Ratio has ranged from 0.13 to 12.74 over the past decade. While the company's 10-year median is 0.65 vs. the industry median of 1.83, Synmosa Biopharma has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PEG Ratio for a Drug Manufacturers company?
The median PEG Ratio among Drug Manufacturers companies is 1.83, based on 350 companies in the industry. Companies in the top quartile (top 25%) have a PEG Ratio significantly above this median, while those in the bottom quartile fall well below. However, PEG Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Synmosa Biopharma's current PEG Ratio of 2.71 is 48.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PEG Ratio mean?
A high PEG Ratio can signal that a stock is expensive relative to its fundamentals. Price-earnings to growth ratio is the ratio of price-earnings to a company's earnings growth rate. View historical data on Synmosa Biopharma and its competitors. For the Drug Manufacturers industry, the median PEG Ratio is 1.83 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Synmosa Biopharma's current PEG Ratio is 2.71, which is 317% above median its own 10-year median of 0.65. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Synmosa Biopharma stock overvalued right now?
Based on GuruFocus' analysis, Synmosa Biopharma (ROCO:4114) is currently considered Modestly Undervalued. The stock's GF Value™ is NT$33.93, compared to a current price of NT$29.60 — trading 12.8% below its estimated fair value. The current PEG Ratio is 2.71, which is 317% above median its 10-year median of 0.65 and 48.5% above the Drug Manufacturers industry median of 1.83. Synmosa Biopharma's overall GF Score™ is 84/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PEG Ratio calculated?
PEG Ratio is calculated from a company's financial statements. For Synmosa Biopharma (ROCO:4114), the current PEG Ratio is 2.71 as of Jul. 20, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Synmosa Biopharma (ROCO:4114) Overvalued in 2026?
Based on GuruFocus' analysis, Synmosa Biopharma stock appears to be undervalued.
The current stock price of NT$29.60 is trading 12.8% below its estimated GF Value™ of NT$33.93.
GuruFocus considers Synmosa Biopharma to be Modestly Undervalued.
Key valuation signals for ROCO:4114:
PEG Ratio: 2.71 (317% above median its 10-year median of 0.65)
GF Value™: NT$33.93 vs. price of NT$29.60 (12.8% below fair value)
Industry Position: 48.5% above the Drug Manufacturers median (#228 of 350)
No single metric tells the full story. See the ROCO:4114 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Synmosa Biopharma Corp is engaged in pharmaceuticals and medical devices, cosmetics, animal drugs, chemical food additives, beverages manufacturing and sales, and environmental drugs wholesale (retail), as well as the import and export of related businesses. Its segments include the Active Pharmaceutical Ingredients segment and the Generic Drugs segment. The Generic Drugs segment derives the majority of the revenue.
84GF Score
Get the complete analysis for ROCO:4114
PEG Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:4114 has been successfully added to your 
